ClinicalTrials.gg
CompletedNCT00050635Updated Nov 19, 2009

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

A Phase 4 interventional study of Sandostatin LAR Depot in Neoplasms and Diarrhea, sponsored by Novartis Pharmaceuticals. Completed at 34 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-11-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Currently there is an ongoing clinical trial for patients with chemotherapy induced diarrhea. This trial is being conducted to evaluate the efficacy of two dose levels (30 mg and 40 mg) of an investigational drug in reducing the occurrence of severe (Grade 3 or 4) diarrhea during chemotherapy. Eligible patients must either have experienced NCI Common Toxicity Grade 1 - 4 chemotherapy-induced diarrhea during previous chemotherapy treatment or be experiencing Grade 1-4 chemotherapy-induced diarrhea currently.

In order to participate in this clinical trial, patients must be male or female 18 years of age or older. Inclusion into this investigational drug trial is based on the protocol entry criteria and a detailed evaluation from a participating trial investigator

02

Conditions studied

  • Neoplasms
  • Diarrhea

Keywords

  • chemotherapy induced diarrhea
  • diarrhea
  • CTID
  • colorectal cancer
  • Sandostatin LAR Depot
  • Sandostatin
  • adverse events
  • side effects
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 150 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • male or female patients of 18 years of age or older, scheduled or expected to receive at least two cycles of chemotherapy over at least a two- month period as primary or therapy for any ,
  • have experienced NCI Common Toxicity Grade 1 - 4 diarrhea during previous chemotherapy treatment or are currently experiencing Grade 1-4 diarrhea due to chemotherapy treatment

Key Exclusion criteria:

  • females who are pregnant or lactating,
  • current use of anticoagulants, except for those who are receiving 1 mg/per day of Coumadin for port maintenance,
  • known to Sandostatin, Sandostatin LAR ® Depot or other related drug or compound,
  • history or presence of Crohn™s disease, ulcerative colitis, sprue, or known C. difficile infection, or any other diarrheal syndrome,
  • WBC \< 3000 /L, \< 75,000 /L, serum creatinine >2.0 mg/dL
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline and at 6 months in the proportion of patients with NCI Grades 3 and/or 4 diarrhea during chemotherapy

07

Study locations

34 sites
  • Kenmar Research Institute
    Burbank, California 91505, United States
  • Bay Area Cancer Research Group
    Concord, California 94520, United States
  • Compassionate Cancer Care medical Group, Inc.
    Fountain Valley, California 92708, United States
  • California Cancer Care, Inc.
    Greenbrae, California 94904-2007, United States
  • Pacific Shores Medical Center
    Long Beach, California 90813, United States
  • Kenmar Research Institute
    Los Angeles, California 90057, United States
  • Oncology Hematology Group of South Florida
    Miami, Florida 33176, United States
  • Pasco Hernando Oncology Associates
    New Port Richey, Florida 34652, United States
  • Mid-Florida Hematology & Oncology Centers, PA
    Orange City, Florida 32763, United States
  • Oncology & Hematology Associates of West Broward
    Tamarac, Florida 33321, United States
  • Creticos Cancer Center
    Chicago, Illinois 60657, United States
  • Decatur Memorial Hospital
    Decatur, Illinois 62526, United States
  • Cancer Care Center
    Bloomington, Indiana 47403, United States
  • Suniti Medical Corporation
    Merrillville, Indiana 46410, United States
  • Genesys Hurley Cancer Institute
    Flint, Michigan 48503, United States
  • Cancer & Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49546, United States
  • Delta Oncology
    Greenwood, Mississippi 38930, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Heartland Hematology Oncology Associates
    Kansas City, Missouri 64118, United States
  • Arch Medical Services/The Center for Cancer Care and Research
    St. Louis, Missouri 63141, United States
  • New Mexico Cancer Care Associates
    Santa Fe, New Mexico 87505, United States
  • North Shore Hematology Oncology
    E. Setauket, New York 11733, United States
  • Raleigh Hematology Oncology Associates, Wake Practice
    Raleigh, North Carolina 27609, United States
  • Dakota Clinic/Odyssey Research Services
    Fargo, North Dakota 58103, United States
  • Nashat Y. Gabrail, MD
    Canton, Ohio 44718, United States
  • North Coast Cancer Care, Inc.
    Sandusky, Ohio 44870, United States
  • Lawrence M. Stallings, MD
    Wooster, Ohio 44691, United States
  • Consultants in Medical Oncology-Hematology
    Drexel Hill, Pennsylvania 19026, United States
  • Regional Hematology Oncology Assoc
    Langhorne, Pennsylvania 19047, United States
  • Oncology Services of Aberdeen
    Borden, South Dakota 57401, United States
  • Jones Oncolgy/Hematology Clinic
    Germantown, Tennessee 38138, United States
  • McFaddin Ward Cancer - TOPA
    Beaumont, Texas 77702, United States
  • Scott & White Hospital/CCPC
    Waco, Texas 76702, United States
  • Oncology & Hematology Associates of SW VA
    Roanoke, Virginia 24014, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2002
First posted
Dec 18, 2002
Start
Dec 2002
Completion
Jul 2003
Last update
Nov 19, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Nov 19, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00050635
Collaborators
Quintiles, Inc.
First posted
Dec 18, 2002
Start date
Dec 2002
Completion
Jul 2003
Last update
Nov 19, 2009
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion